; Opioid Use Disorder Market Size, Share, Trend, Forecast, 2034

Opioid Use Disorder Market

Opioid Use Disorder (OUD) Market Size, Share, and Analysis, By Drug Class (Buprenorphine, Methadone, and Naltrexone), By Route of Administration (Oral, Sublingual, and Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Region (North America, Europe, Asia-Pacific, and Rest of the World), And Regional Forecast 2024-2034

Published on: Apr-2024
Report Code: FG HC 01957
No. of Pages: 170-350
Report Format: PDF

Opioid Use Disorder (OUD) Market is anticipated to grow at a CAGR of 10% in the forecast period (2024-2034), with the market size valued at USD 3.3 billion in 2023 and projected to reach USD 9.5 billion by 2034.

Product Overview

Opioid Use Disorder (OUD) is a chronic medical illness that involves a problematic pattern of opioid usage and causes substantial pain or suffering. Those with opioid use disorder usually display an uncontrollable need to use opioids despite severe effects, such as health challenges and interpersonal issues. This disorder can emerge from various sources, such as the misuse of prescription opioids, along with illicit drug usage or even medically supervised opioid treatment. In addition, opioid use disorder can involve serious symptoms such as extreme cravings, withdrawal symptoms after stopping, and an inability to control consumption. Furthermore, treatment for OUD involves an integrated approach, such as medication and therapy, to ensure long-term recovery. Therefore, timely intervention and extensive support are crucial for tackling this complicated and demanding illness.

Market Highlights

Opioid Use Disorder (OUD) Market is expected to exhibit a CAGR of 10% during the forecast period, 2024-2034

Opioid Use Disorder (OUD) Market is anticipated to reach USD 9.5 billion, growing at a CAGR of 10% during the forecast period, due to increasing awareness and proactive governmental efforts to address the opioid crisis. The expansion of the opioid use disorder market is attributed to the rising prevalence of OUD and the development of modern therapies to meet the evolving needs of patients. In addition, major industry players are investing in the creation of new medications and therapies, such as long-acting formulations and non-opioid alternatives. Moreover, while specific regions may have different approaches for the prevention and treatment of opioid misuse, collaboration among stakeholders remains crucial for the industry. This collaborative effort ensures constant innovation in the opioid use disorder market, which ultimately contributes to the goal of reducing the impact of opioid addiction on public health.

 

Source: Fatpos Global

Opioid Use Disorder (OUD) Market Segmentation

Buprenorphine segment will dominate owing to its effectiveness in managing OUD symptoms

Opioid Use Disorder is segmented based on Drug Class into Buprenorphine, Methadone, and Naltrexone. The buprenorphine segment is projected to dominate the opioid use disorder market as buprenorphine is considered a preferred treatment due to its efficiency in managing withdrawal symptoms while simultaneously reducing the risks of overdose. Moreover, buprenorphine can be prescribed in office-based settings, which improves its accessibility among patients. The treatment delivery of buprenorphine is flexible due to the availability of various formulations such as sublingual tablets, films, and implants. Additionally, continuous research that is focused on improving buprenorphine formulations, such as long-acting injectables, is improving its treatment and outcomes. These factors reflect the effectiveness and flexibility of buprenorphine in addressing the needs of individuals suffering from opioid use disorder.  

Hospital Pharmacies segment will lead as hospitals are primary centres for OUD management

Opioid Use Disorder Market is segmented based on Distribution Channels into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The hospital pharmacies segment is anticipated to be leading the Opioid Use Disorder market as hospitals serve as primary hubs for treating severe cases of opioid use disorder, that require immediate medical attention and monitoring. Hospital pharmacies play an important role in supplying crucial medications for the management and stabilization of patients, such as opioid agonists and antagonist therapies. Additionally, hospital pharmacies provide comprehensive support services, such as counselling and education, which are essential for effective opioid use disorder management. Therefore, the dominance of hospital pharmacies in the opioid use disorder market highlights their role in delivering care to individuals grappling with opioid addiction. 

Market Dynamics

Growth Drivers

Growing Awareness and Treatment Options to Expand the Market

Opioid Use Disorder market is experiencing a substantial rise as people are becoming increasingly aware of the dangers of opioid overuse and addiction. These people are recognizing the obvious symptoms and indicators of OUD, which is encouraging them to get help for themselves or their loved ones. This greater understanding is the result of extensive educational efforts and community engagement programs that are focused on removing the stigma associated with addiction and improving access to treatment services. Therefore, healthcare providers are experiencing high levels of engagement and treatment pursuit by patients. This surge in demand creates a greater need for OUD interventions and therapies, thereby highlighting the growth trajectory of the opioid use disorder market.

Innovations in Technology and Treatment Will Positively Influence the Market

Improvements in medical technology and pharmaceutical research are promoting innovation in the treatment of opioid use disorder. Pharmaceutical companies are crafting new medications and therapies that are customized to tackle the significant challenge of opioid addiction. These innovations include numerous solutions, from long-acting formulations to abuse-deterrent formulations and non-opioid alternatives. Moreover, the development of diagnostic tools and telemedicine solutions is transforming the delivery of medicines and expanding the reach of treatment services for OUD-affected individuals. Consequently, these improvements are enhancing the treatment outcome and providing better satisfaction to patients, thereby displaying a major step forward in addressing the challenges of opioid use disorder.

Restraints

Legal and Regulatory Restrictions are a Significant Challenge to Market Growth

Regulatory challenges and legal restrictions present significant hurdles to the growth of the opioid use disorder market, despite high demand for its treatments. Opioid prescription is governed by strict regulations, due to which distribution and dispensing of OUD medicines become difficult. Additionally, the approval process for new OUD treatments is often lengthy and complex and involves extensive clinical trials and regulatory scrutiny. As a result, pharmaceutical companies can encounter delays in introducing new therapies, which can significantly limit treatment options for patients. Therefore, navigating regulatory challenges is essential in the OUD market to ensure easy access to effective treatments while adhering to different regulations.

Recent Developments

  • In 2023, Reckitt Benckiser Pharmaceuticals acquired the Suboxone film business from Indivior for $1.6 billion, strengthening its position in the buprenorphine market. While the company introduced Suboxone in a new abuse treatment formulation in the US.
  • In 2023, Johnson & Johnson announced plans to divest their Xiydro ER opioid drug following various complications. The company recently acquired Abiomed, a medical device company focused on diversified medical segments.
  • In 2023, Teva Pharmaceuticals launched their generic Suboxone film in the US, while the company announced its plans to share $4.25 billion with states and local governments.
  • In 2023, Titan Pharmaceuticals announced a positive result from a Phase 2 clinical trial of their lead OUD candidate, Probuphine. Camurus AB announced a partnership with Braeburn Pharmaceuticals to develop and commercialize Braeburn's long-acting buprenorphine injection in Europe.
  • In 2023, Alkermers plc launched Vivitrol in a new long injectable formulation in the US. The company announced its research collaboration with Pfizer to develop new pain medications with less potential for misuse.

Opioid Use Disorder (OUD) Market

Key Players:

Regional Analysis

Opioid Use Disorder Market is segmented based on regional analysis into five major regions: North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. The Asia Pacific region dominates the Opioid Use Disorder market as the region has experienced a notable surge in opioid misuse and addiction due to various socio-economic factors, such as cultural norms and high opioid availability. In addition, growing awareness of OUD and its associated health risks has created greater demand for treatment options throughout the Asia Pacific region. Furthermore, governmental initiatives that are aimed at combating the opioid crisis and improving healthcare access have further resulted in growth across the Asia Pacific region.

Furthermore, the European region is expected to rise substantially as Europe has seen a concerning surge in opioid-related fatalities and addiction rates across the continent. This trend has stimulated high attention and investment from policymakers and pharmaceutical companies toward OUD treatment and prevention efforts across the European region.

Source: Fatpos Global

Impact of COVID-19 on Opioid Use Disorder (OUD) Market

COVID-19 pandemic has significantly impacted the opioid use disorder market in several ways. The pandemic worsened existing challenges for individuals with OUD, such as social isolation, economic stress, and limited healthcare access, which resulted in high opioid misuse and relapse rates. Moreover, the focus of the healthcare system on managing the pandemic diverted resources from OUD treatment, which caused low access to care and support services for opioid use disorder patients. Additionally, disruptions in the pharmaceutical supply chain and restrictions on non-essential medical services complicated the delivery of OUD medications and therapies. Therefore, the pandemic highlighted the need for resilient healthcare systems which is capable of addressing public health crises while ensuring continuous access to treatments and support services for individuals with OUD.

Opioid Use Disorder (OUD) Market is further segmented by region into:

  • North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
  • Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil, and Rest of Latin America
  • Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey, and Rest of Europe
  • Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
  • Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa, and Rest of MENA

Opioid Use Disorder (OUD) Market Scope and Segments:

ATTRIBUTE

  DETAILS

Study Period

2018-2034

Base Year

2023

Forecast Period

2024-2034

Historical Period

2019-2022

Growth Rate

CAGR of 10% from 2024-2034

Unit

Value (USD Billion)

Segmentation

Main Segments List

By Drug Class

  • Buprenorphine
  • Methadone
  • Naltrexone

By Route of

Administration

  • Oral
  • Sublingual
  • Intravenous

By Distribution

Channels

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Frequently Asked Questions (FAQ):

Opioid Use Disorder (OUD) Market size was valued at USD 3.3 billion in 2023 and is projected to reach the value of USD 9.5 billion in 2034, exhibiting a CAGR of 10% during the forecast period.

Opioid Use Disorder is a medical-related condition that is categorized by misuse of opioids, including painkillers or illicit substances like heroin.

The Buprenorphine segment and Hospital Pharmacies segment accounted for the largest Opioid Use Disorder (OUD) Market share.

Key players in the Opioid Use Disorder (OUD) Market include Reckitt Benckiser Pharmaceuticals, Johnson & Johnson, Purdue Pharma, Teva Pharmaceuticals, Mallinckrodt Pharmaceuticals, Indivior, Pfizer Inc., GlaxoSmithKline plc, Alkermes plc, Titan Pharmaceuticals, Camurus AB, BioDelivery Sciences International, Inc., Braeburn Inc., Orexo AB, Insys Therapeutics, and Other Prominent Players.

The factors driving the opioid use disorder market include growing awareness and treatment options, along with innovations in treatment technology.

Select License Type

$3199

Report accessible by 1 user only

In case you require a hard copy, there will be an additional charge of $500. Please email us at info@fatposglobal.com with your request

Call us

Research Assistance

US : +1 (716) 218-3733
UK : +44 (208) 1235555



Select License Type

$3199

Report accessible by 1 user only

Sample Request

Client Testimonials

FATPOS CLIENT Appriciation DURING THE PROJECT

Clients